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S64Objectives: We compared aortic root reconstructions using conduits with biological valves and mechanical
valves.
Methods: Of 597 patients (1995–2008), 307 (mean age 71 years [23–89 years]) had biological valves and 290
(mean age 51 years [21–82 years]) had mechanical valves. The subgroup of 242 patients aged 50 to 70 years in-
cluded 133 with biological and 109 with mechanical valves.
Results: Overall hospital mortality was 3.9% with biological valves (n ¼ 15; elective: 3.7% [n ¼ 10]) versus
2.8%with mechanical valves (n¼ 8; elective: 1.4% [n¼ 3]). In patients 50 to 70 years, age greater than 65 years
(relative risk: 3.3 [P ¼ .0001]), clot (relative risk: 2.5 [P ¼ .05]), coronary artery disease (relative risk:3.5
[P< .0001]), and degenerative etiology (relative risk: 0.4 [P ¼ .006]) were independent risk factors for long-
term survival (after postoperative day 30); there was no difference in long-term survival between biological
and mechanical valves (relative risk: 0.9 [P ¼ .74]). The linearized rate for valve/ascending aorta reoperation
was 0.86%/pt-y (2 in 2310 pt-y) after mechanical valves and 2.5%/pt-y (4 in 1586 pt-y) after Bentall procedures
with the biological valve.
Conclusions: The choice of valve for aortic root reconstruction seems to have no influence on long-term out-
come. Emergency operation and the presence of clot/atheroma have a significant impact on short-term outcome.
Reoperation for either ascending aorta and/or aortic valve is low. (J Thorac Cardiovasc Surg 2010;140:S64-70)Aortic root replacement with reattachment of the 2 main cor-
onary arteries was originally described by Bentall and De
Bono.1 The operation has undergone many alterations dur-
ing the past 3 decades.2 Notable adaptations have been the
creation of an aortic cuff around the coronary ostia and ex-
tensive mobilization and attachment of the coronary buttons.
Although the operation was originally designed to treat pa-
tients with aortic root aneurysms, the indications for radical
root replacement have expanded.3-5
The Bentall procedure has led the way for the develop-
ment of other techniques for root replacement, such as
aortic valve–sparing procedures. The potential advantage
of these procedures is freedom from the need for anticoagu-
lation and consequent low morbidity.6 Although the Bentall
procedure is a durable operation, with a low ascending
aorta and valve reoperation rate, the replacement of the aor-
tic valve with a mechanical prosthesis carries a significante Departments of Cardiothoracic Surgery and Anesthesia, Mount Sinai School
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The Journal of Thoracic and Cardiovascular Surglifetime risk of both thromboembolism and major hemor-
rhagic complications.3
The choice of which operation to perform for aortic root
disease is multifaceted and influenced by the preferences
of both patient and surgeon. The young patient (<40 years
old) who wishes to avoid anticoagulation, or in whom it is
contraindicated, will likely benefit from an aortic valve–
sparing procedure6 if he or she has a competent aortic valve
and minimal valve deformity. Patients over the age of 70
years are likely to benefit most from aortic root replacement
with a biological valve (BV), which has a low probability of
rapid structural deterioration in older patients and a low rate
of stroke and reoperation.7 However, patients between 50
and 70 years old are often offered a choice between a me-
chanical valve (MV) and a stented bioprosthesis (BV) for
the Bentall procedure.
We report our experience with 597 consecutive patients
who have undergone a Bentall procedure with an MV or
stented BV during a 13-year period. We highlight the
long-term outcomes of patients as a function of valve choice.
In the 50- to 70-year age group, in which either valve type
has been considered reasonable for some years, we compare
the outcomes of the Bentall procedure with MV and BV.METHODS
Our analysis includes patients operated on from 1995 to 2008; before
1995, only a limited number of Bentall operations with the BV were per-
formed (BV ¼ 3, MV ¼ 133). The study was approved by the institutional
review board without a requirement for individual patient consent.ery c December 2010
Abbreviations and Acronyms
BV ¼ biological valve
CABG ¼ coronary artery bypass grafting
MV ¼ mechanical valve
SMR ¼ standardized mortality ratio
Etz et al Aortic Symposium 2010A total of 597 were analyzed retrospectively: 103 (17.2%) had urgent or
emergency procedures and 49 (8.2%) were admitted with acute type A dis-
section. Further patient characteristics are listed in Table 1.
In most patients, the indication for a Bentall procedure was the presence
of aortic valve dysfunction severe enough to warrant aortic valve replace-
ment; for these patients, the aortic root was replaced if the ascending aorta
exceeded 4 to 4.5 cm in diameter and the patient’s life expectancy was an-
ticipated to be greater than 10 years. In patients with bicuspid aortic valve
but without severe valvular dysfunction, the Bentall procedure was done
if the ascending aortic diameter was greater than 5.5 cm or if they had
type A dissection.
Surgical Technique
All patients included in this study had a button Bentall operation, a mod-
ification of the original technique described by Kouchoukos and coworkers2
in 1991. All operations were performed with an open distal anastomosis us-
ing a period of deep hypothermic circulatory arrest, often with hemiarch re-
placement, but occasionally involving replacement of the entire arch. Our
current technique and its rationale have been previously described in detail.8
In brief, cannulation for cardiopulmonary bypass was through the femo-
ral artery in the majority of patients through 1999. In 2000, cannulation of
the right axillary artery became the standard approach. The temperature was
lowered to 20C during the proximal aortic reconstruction and then to 12C
to 15C before circulatory arrest. A jugular venous catheter was placed to
measure mixed venous saturation during cooling.
After sizing of the aortic annulus, a series of pledget-supported mattress
sutures was placed from the ventricular to the aortic aspect of the annulus for
fixation of a heterograft. Annular stitches engaged both the valve sewing
ring and the vascular graft to facilitate subsequent replacement of the hetero-
graft valve within the conduit. For a prosthetic MV, the sutures were placed
from the aortic to the ventricular aspect of the annulus to effect intra-annular
fixation of the valve. A composite of a St Jude Medical valve (St Jude Med-
ical, Inc, St Paul, Minn) and a Hemashield graft (Boston Scientific Corp,
Wayne, NJ) was used in MV cases. The BV option involved a homemade
composite of a pericardial valve (Edwards Lifesciences LLC, Irvine, Calif)
or porcine valve (Medtronic, Inc, Minneapolis, Minn) and a Hemashield
graft. After the proximal suture line was completed, the diseased aortic seg-
ment was resected, and buttons including the coronary ostia were excised.
The first centimeter of the coronary arteries was mobilized, and the buttons
were implanted in an end-to-side fashion with a running suture incorporat-
ing a polytetrafluoroethylene (Teflon) felt strip to reinforce the adventitial
surface of the coronary arteries.
Choice of Valve: BV Versus MV
Patients older than 65 years of age and those with contraindications to
anticoagulation were generally advised to opt for a BV. Patients younger
than 55 years of age usually received an MV unless a contraindication to
anticoagulation was present, but some active younger patients preferred
a BV despite understanding that this would lead eventually to a second
operation.
Patients with a BV were advised to take 325 mg of aspirin daily for the
first 3 months. Although no sodium warfarin (Coumadin) was mandated by
the surgeons, some patients were placed on a long-term regimen of
anticoagulants for other indications by their referring physicians duringThe Journal of Thoracic and Carfollow-up. All patients with MVs were treated with warfarin, with a target
international normalized ratio of 2.0 to 2.5.
Follow-up
A retrospective review of these patients was conducted using data gath-
ered contemporaneously and supplemented from patient medical records.
Follow-up information was gathered from yearly routine computed tomo-
graphic scans (with contrast) of the aorta, direct telephone interview of
the patient or a close relative, and contact with the referring physician.
Statistical Methods
Data were entered in an Excel (Microsoft Corp, Redmond, Wash)
spreadsheet and transferred to a SAS (SAS Institute, Inc, Cary, NC) file
for data description and analysis. Characteristics are described as percent-
ages, medians, or as means and standard deviations. Kaplan–Meier life
tables were calculated for the risk of death.
Follow-up was measured from the date of the operation to the earlier of
either the date of death or the last contact alive. Short-term mortality or hos-
pital mortality was defined as death during the initial hospitalization regard-
less of number of days, or death within 30 days of the procedure among
patients discharged alive. Risk factors for short-term mortality were ana-
lyzed by c2 tests and multiple logistic regression.
Long-term follow-up was calculated for survivors of hospital mortality,
commencing 30 days after the procedure and terminating at the earlier of ei-
ther death or last contact alive for survival estimates. For long-term adverse
events, follow-up time was terminated at the time of their occurrence.
Long-term adverse events included death and morbid conditions as defined
by Edmunds and coworkers9: stroke, hemorrhage necessitating transfusion
or hospitalization, peripheral embolization, and endocarditis. The Cox pro-
portional hazards model and Kaplan–Meier survival curves, and their com-
parisons with New York State mortality, were used to analyze and describe
long-term survival. Annualized person-year event rates were estimated for
long-term survival and for adverse events. Poisson regression provided signif-
icance tests of standardized mortality ratios (SMRs) of observed deaths rela-
tive to the number of deaths expected on the basis of New York State mortality
rates for comparable ages, calendar time, follow-up years, and for tests com-
paring SMRs.
Because of the demographic differences between the groups as a whole,
detailed comparisons of outcomes between patients undergoing Bentall pro-
cedures with MV and BV were limited to the age group between 50 and 70
years. For similar reasons, long-term outcomes were assessed using compar-
isons between age- and sex-matched normal New York State control popu-
lations for each valve type. Analysis of risk factors for early and long-term
mortality could not be carried out in some subgroups in which there were
very few deaths.RESULTS
Preoperative Patient Characteristics
The demographic data, preoperative risk factors, and oper-
ative details of the 597 patients analyzed are summarized in
Table 1. There were 458 men and 139 women, with a median
age of 63 years (21–89 years); there were 307 BV and 290 MV
operations. Hypertension was present in 52% of the patients;
coronaryarterydisease wasevident in26%; 25%had a history
of smoking; and 110 (18.4%) patients had acute dissection.
The mean diameter of the ascending aorta was 6.0  1.2 cm.Intraoperative Characteristics
Approximately 32% of the patients underwent a concom-
itant procedure; 26% (155 patients) had coronary arterydiovascular Surgery c Volume 140, Number 6S S65
TABLE 1. Demographics, preoperative clinical and operative characteristics
Variable All patients (n ¼ 597) Mechanical valve (n ¼ 290) Biological valve (n ¼ 307)
Age (median) in years 63 (21–89) 51 (21–82) 71 (2389)
Male 458 (76.7) 233 (80.3) 225 (73.3)
Risk factors
Hypertension 313 (52.4) 132 (45) 181 (59)
Atheroma 26 (4.4) 4 (1.4) 22 (7.2)
Clot 26 (4.4) 6 (2.1) 20 (6.5)
Smoking 155 (25.9) 73 (25.2) 82 (27)
IDDM 39 (6.5) 20 (6.9) 19 (6.2)
COPD 20 (3.4) 8 (2.8) 12 (3.9)
CAD (coronary artery disease) 151 (25.3) 46 (15.9) 105 (34.2)
Neurologic 39 (6.5) 14 (4.8) 25 (8.1)
Renal failure (dialysis) 8 (1.3) 1 (.34) 7 (2.3)
Etiology
Atherosclerosis 64 (10.7) 14 (4.8) 50 (16.3)
Degenerative 332 (55.6) 149 (51.4) 183 (59.6)
Dissection 110 (18.4) 62 (21.4) 48 (15.6)
Other 91 (15.2) 65 (22.4) 26 (8.5)
Bicuspid aortic valve 168 (28.1) 98 (34) 82 (27)
Marfan 14 (2.3) 13 (4.5) 1 (0.32)
Timing of operation
Emergency 58 (9.7) 43 (14.8) 15 (4.9)
Urgent 45 (7.5) 25 (8.6) 20 (6.5)
Significant aortic valve
insufficiency (AR)
340 (57) 174 (60) 166 (54.1)
Operative data
Ascending aortic diameter (mean) 60  1.2 5.7  1.2 6.0  1.2
Previous cardiac surgery 109 (18.3) 57 52
Extent of aortic resection
Hemiarch 228 (38.2) 113 (39.0) 115 (57.5)
Arch, other 34 (15.7) 13 (4.5) 21 (6.8)
Ascending only 335 (56.1) 164 (56.6) 171 (55.7)
Concomitant surgery
CABG  other 155 (26.0) 46 (15.9) 109 (35.5)
Not CABG 32 (5.4) 15 (5.2) 17 (5.5)
Neither 410 (68.7) 229 (79.0) 181 (59.0)
CPB time (min) 252  60 244  61 260  58
HCA time (min) 24.2  13.6 24.4  12.8 23.9  14.3
Aortic crossclamp time (min) 176  49 168  48 183  49
Minimal esophageal temp (C) 13.3  5.3 13.2  5.2 13.3  5.3
AR, Aortic regurgitation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass;
HCA, hypothermic circulatory arrest; IDDM, insulin-dependent diabetes mellitus; CABG, coronary artery bypass graft procedure; other, additional valve or aortic operation;
min, minutes.
Aortic Symposium 2010 Etz et albypass grafting (CABG) with or without another procedure
and 5.4% underwent another concomitant procedure. The
Bentall procedure was a reoperation in 109 (18.3%)
patients. The mean aortic crossclamp time was 176.8 
49 minutes, and total hypothermic circulatory arrest time
was 24.2  13.6 minutes. Further operative characteristics
are outlined in Table 1.
Short-Term Outcomes
Overall 30-day mortality was 3.9%: 2.8% for MV pa-
tients and 4.9% for BV patients. Mortality for emergency
operations was 9.7% (10/103). Sixteen (2.7%) patientsS66 The Journal of Thoracic and Cardiovascular Surghad a permanent stroke, including 7 MV (2.4%) and 9 BV
patients (2.9%). Temporary neurologic dysfunction oc-
curred in 14.4%, renal failure in 2.2%, and pulmonary fail-
ure in 13%. The mean intensive care unit stay was 3.8 days,
and the mean hospital stay was 12.8 days. Further short-term
adverse outcomes are outlined in Table 2.
Risk Factors for Hospital Mortality
Various risk factors were analyzed for their impact on
hospital mortality (Table 3). In all patients older than 20
years, the risk factors associated with mortality were clot
(P ¼ .005), emergency operation (P< .001), concomitantery c December 2010
TABLE 2. In-hospital post-operative complications
Complications Total Mechanical Biological
Death 23 (3.9) 8 (2.8) 15 (4.9)
Bleeding 20 (3.4) 9 (3.1) 11 (3.5)
Cardiac 65 (11) 36 (12.4) 29 (9.4)
Neurologic
Temp 86 (14.4) 35 (12) 51 (16.6)
Perm 16 (2.7) 7 (2.4) 9 (2.9)
Pulmonary 78 (13) 41 (14.1) 37 (12)
Renal 13 (2.2) 7 (2.4) 6 (2.0)
Infection 29 (4.9) 18 (6.2) 11 (3.6)
Temp, Temporary neurologic dysfunction; Perm, permanent neurologic injury.
TABLE 4. Predictors of Long-term mortality
Long-term survival
(all ages  20 y)
Long-term survival
(50–70 y group)
MV and BV MV and BV (n ¼ 48)
RR (95% CI) P value RR (95% CI) P value
Age>65 y 3.3 .0001
Degen 0.4 .006
Clot 2.5 .05





MV, Mechanical valve; BV, biological valve; RR, relative ratio; CI, confidence
interval; Degen, degenerative; CAD, coronary artery disease; Emerg, emergency
operation; CABG, coronary artery bypass graft procedure; Reop, reoperation; smoker,
history of smoking.
Etz et al Aortic Symposium 2010CABG (P ¼ .007), reoperation (P ¼ .004), and smoking
(P ¼ .02). The type of valve implanted—BV or MV—did
not influence hospital mortality (P ¼ 0.19). In the 50- to
70-year age group, emergency (P ¼ .005) and clot
(P ¼ .001) were risk factors associated with in-hospital
mortality.
Of a number of possible preoperative risk factors for in-
hospital mortality analyzed, clot, reoperation, smoking,
emergency operation, and CABG emerged as significant.
None of the 236 patients without any of these risk factors
died. With 1 risk factor, in-hospital mortality was 3.3%
(8/242), with 2 risk factors it was 9.4% (9/96), and with 3
preoperative risk factors, 26.1% (6/23).Long-Term Outcomes
During follow-up beyond 10 years (median, 6.6 years;
range, 0–14.6 years), there were 104 BV and 49 MV late
deaths. A total of 421 patients were alive according to the
Social Security Death Index database, and 383 (91%) of
the patients or next of kin were contacted by telephone:
212 (55.3%) with MV and 171 (44.6%) with BV. Long-
term follow-up for the 50- to 70-year age was complete inTABLE 3. Predictors of hospital mortality
Hospital mortality
(aged  20 y)
Hospital mortality
(aged 50–70 y)
MV and BV (n ¼ 23) MV and BV (n ¼ 10)
OR (95% CI) P value OR (95% CI) P value
Age>65 y
Degen
Clot 5.2 1.6–16.4 .005 11.1 2.5–40.9 .001
CAD
Emerg 8.7 3.1–24.3 <.0001 10.1 2.1–58.3 .005
CABG 3.7 1.4–9.3 .007
Reop 4.0 1.5–10.1 .004
Smoker 3.0 1.2–7.3 .02
MV 0.5 0.2–1.4 .19
MV, Mechanical valve; BV, biological valve; OR, odds ratio; CI, confidence interval;
Degen, degenerative; CAD, coronary artery disease; Emerg, emergency operation;
CABG, coronary artery bypass graft procedure; Reop, reoperation; smoker, history
of smoking.
The Journal of Thoracic and Car175 (92.6%) of 189 patients. Of the 383 patients contacted,
41 patients or next of kin reported a stroke, and 35 patients
had a major bleeding event that required either transfusion or
hospitalization.
The risk factors for long-term survival were calculated for
both the older than 20 years and the 50- to 70-year-old age
groups (Table 4). In the older than 20 years, the only risk
factor associated with mortality was CAD (P ¼ .002). In
the 50- to 70-year-old patients, age older than 65 years
(P ¼ .0001), CAD (P< .001), and clot (0.05) were risk fac-
tors associated with long-term mortality. The presence of a
degenerative aneurysm was protective against long-term
mortality (RR¼ 0.4, P ¼ .006).
The SMR of our cohort in comparison with New York
State age- and sex-matched population, starting 30 days
postoperatively, was 1.5 for BV (P< .0001) and 1.7 for
MV (P< .0001). There was no significant difference in
the relative risk between BV and MV patients (P ¼ .58)
on the basis of valve type. The SMRs for women and men
in both the BV and MV groups were significantly higher
than those of the New York State age- and sex-matched pop-
ulations described in Table 5. The long-term survival for BV
and MV patients in the 50- to 70-year age group is shown in
Figure 1.
The impact of the significant preoperative risk factors on
long-term survival was calculated using New York State
age- and sex-matched mortality rates. Again, the important
preoperative risk factors were clot, CABG, reoperation,TABLE 5. Standardized mortality ratio of our cohort versus New
York State age- and sex-matched population
Mechanical Biological
Men 66/51.8 ¼ 1.3 (P ¼ .03) 39/23 ¼ 1.7 (P ¼ .0005)
Women 38/16.4 ¼ 2.3 (P< .0001) 10/5.8 ¼ 1.7 (P ¼ .05)
Totals 104/68.2 ¼ 1.5 (P< .0001) 49/29 ¼ 1.7 (P< .0001)
diovascular Surgery c Volume 140, Number 6S S67
FIGURE 1. Kaplan–Meier curve of 242 patients, aged 50 to 70 years, after
Bentall procedure with biological (n ¼ 133) or mechanical (n ¼ 109) valve
(survival is calculated starting from the procedure).
Aortic Symposium 2010 Etz et alemergency operation, and smoking. The SMRs for patients
with up to 3 preoperative risk factors were analyzed (Table
6), and their long-term survival curves are shown in
Figure 2.
Adverse Outcomes and Event Rates
Six patients required reoperation on either the ascending
aorta or aortic valve during follow-up: 2 with MVs and 4
with BVs. The linearized rate for valve/ascending aortic re-
placement for both valve types was 1.54%/pt-y (6/3896
person-years): 0.86%/pt-y (2/2310 pt-y) after MV and
2.5%/pt-y (4/1586 pt-y) after the BV Bentall procedure.
The adverse event rate for the 50- to 70-year age group
was defined as the occurrence of stroke and/or death. The
linearized rate of stroke (12/126) and/or death (20/126) for
MV Bentall was 3.0%/pt-y (32 in1054 pt-y). The linearized
rate of stroke (10/102) and/or death (23/102) for BV Bentall
was 5.6%/pt-y (33 in 585 pt-y).COMMENTS
In accord with the reports of others, we experienced sig-
nificant reduction in hospital mortality as our experience
with aortic root replacement increased. Before 1990, the
mortality for an MV Bentall procedure was 9.1%; mortality
decreased to 1.1% after 2005. Similar favorable outcomes
were seen in the BV Bentall cases: between 1993 andTABLE 6. Standardized mortality ratio of patients> 20 years with ident
sex-matched population
No. of factors N Median year Median age No. of
0 236 2002 57 3
1 234 2000 63 6
2 87 1999 68 3
3 17 1999 67
SMR, Standardized mortality; 95% CI, confidence interval; N, number of patients.
S68 The Journal of Thoracic and Cardiovascular Surg1998 there was a mortality of 10.9%, and after 2005 the
mortality was reduced to 4.2%. For the years covered in
this study, the overall in-hospital mortality was 3.9%.
There are several probable reasons for the higher mortal-
ity in BV than in MV patients: a higher median age (71 vs 51
years) and an increased burden of atherosclerosis, reflected
by a greater number of CABG operations: 34% vs 15%.
In the BV group, patients requiring CABG had a 5-fold in-
crease in mortality over those without CABG (Table 3).
The BV group had more patients with a preoperative history
of neurologic events, further underscoring the likelihood of
underlying aortic atherosclerosis, cerebrovascular disease,
and clot in this cohort. The difference in mortality is ex-
pected, given our practice of implanting BVs in older pa-
tients and those with multiple, life-limiting comorbidities.
Despite a myriad of etiologies for ascending aorta dilata-
tion and valve dysfunction, the Bentall operation can be per-
formed safely in an elective setting with a mortality of 2.6%.
Patients without any preoperative risk factors can proceed
with surgery with favorable short- and long-term survival
(Figure 2). In our prior report on the Bentall operation, the
in-hospital mortality for the subgroup of patients less than
65 years of age without need for concomitant procedures
was 0.7%.10 An emergency or urgent aortic root replace-
ment carries a significantly higher operative mortality:
9.7%: Emergency operation increases the risk of operation
5-fold, and the presence of clot or atheroma carries an
8-fold increase in hospital mortality. In a patient with 2 or
3 preoperative risk factors, the operative risk increases
6-fold to 26-fold, and long-term survival is less favorable.
Bachet and associates11 have reported a 21% hospital mor-
tality for aortic root replacements in acute aortic dissection,
indicating the technical challenge of this operation in man-
aging delicate, friable tissue, and the negative impact of mal-
perfusion and thromboembolism. The emergency Bentall
cohort represents a mixture of patients that include acute aor-
tic dissections, ruptured aneurysms, and pseudoaneurysms,
which are likely to be associated with a higher prevalence
of clot or atheroma and the need for ad hoc coronary revas-
cularization (Table 1).
The valve-related morbidity cannot be estimated accu-
rately in this large population of patients because the cause
of death was available in only 76 of 176 late deaths; 91% of
the living patients (383/421) or their relatives, however,
were interviewed. A combined total of 41 strokes and 35ified preoperative risk factors compared to New York State age- and
deaths Expected deaths SMR 95% CI P value
8 32.2 1.2 (.86, 1.6) .31
8 44.5 1.5 (1.2, 1.9) .0005
8 23.1 1.6 (1.2, 2.3) .002
9 3.2 2.8 (1.4, 5.3) .002
ery c December 2010
FIGURE 2. Kaplan–Meier curve of the long-term survival of patients after
Bentall operation according to the number of identified preoperative risk
factors (smoking, coronary artery bypass graft, reoperation, emergency,
and clot).
Etz et al Aortic Symposium 2010major hemorrhagic events were tabulated from patients both
dead and alive. Our previous publication with BV Bentall
operations estimated the rate of stroke at 0.85/100 pt-y
and significant hemorrhage as 0.3/100 pt-y.7 In patients
with bicuspid valves, the linearized stroke rate was 0.7/
100 pt-y and that of hemorrhage, 0.5/100 pt-y.3 In the 50-
to 70-year age group, the linearized adverse event rate
(stroke and/or death) was 3.0%/pt-y (32/1054 pt-y) for
MV and 5.6%/pt-y (33/585 pt-y) for BV. The favorable
long-term survival in the 50-to 70-year age group irrespec-
tive of valve type suggests good compliance with and
management of anticoagulation and a low incidence of
valve-related complications. The low absolute number of
adverse events in the contacted patients may reflect contem-
porary strategies—principally lower international normal-
ized ratio goals and self-management of anticoagulation
therapy—in patients with MV.12 In addition to lower throm-
boembolic and bleeding events, Koertke and colleagues13
have shown improved survival in self-managed patients.
Bryne and coworkers14 reported a similar 5-year freedom
from valve-related complications with BV and MV aortic
root replacements (BV 93% vs MV 86%).
We7 previously reported the unexpected finding of poorer
long-term survival in female patients after aortic root recon-
struction compared with an age-matched population. In the
present analysis, female patients were twice as likely to
die during follow-up as in a matched population. Moreover,
in general, women have a poorer outcome after cardiovascu-
lar surgery than men.15,16 In several studies, preoperative
risk profile, incidence of neurologic complications, and
incomplete revascularization with CABG have all been
significantly higher in women.
Observed deaths in both men and women were signifi-
cantly higher than expected in a New York State age- andThe Journal of Thoracic and Carsex-matched population (Table 5). We previously showed
that patients with bicuspid aortic valve had a normal life ex-
pectancy after a Bentall operation.3 In the current analysis,
patients with bicuspid aortic valve composed only one third
of the cohort, albeit 50.6% of the degenerative ascending
aortic aneurysms, the major etiology leading to a Bentall op-
eration (55% overall). Degenerative aneurysms had a favor-
able effect on long-term outcome in the 50- to 70-year age
group (relative risk ¼ 0.4, P ¼ .006). There are numerous
other diseases treated with the Bentall procedure that may
account for a diminished long-term survival. After proximal
aortic surgery for aortic dissection, for example, patients
have a late risk of death approximately twice that of a healthy
population.17
The current data may suggest a modification to current
clinical practice with respect to valve selection. Patients un-
der the age of 50 years may continue to select an aortic MV
for a Bentall operation owing to the low long-term valve-
related complication rate suggested by our data and under-
scored by other authors.12-14 Contemporary anticoagulation
protocols, self-monitoring, and new, safer, predictable anti-
coagulants on the horizon make aortic MVs attractive to the
young patient. However, proper patient selection in this age
group may allow patients with aortic valve–sparing root
replacement to fare as well or better in the long term
with respect to need for reoperation and incidence of mor-
bid complications. Patients in the 50- to 70-year age group
may also reasonably be offered a BV Bentall procedure, in-
asmuch as valve-related complications and need for reoper-
ation are relatively low. Furthermore, reoperation for
prosthetic BV dysfunction requires only a valve replace-
ment rather than rereplacement of the composite root,
reducing perioperative mortality and morbidity. In addition,
percutaneous or transapical aortic valve replacement may
become routine methods for elderly patients requiring
reoperation.
This study of 597 patients highlights the excellent short-
and long-term outcomes with the Bentall procedure for
a multitude of aortic diseases. The strength of the operation
lies in its wide applicability and reproducibility. The choice
of valve type does not affect early or late outcomes, as
shown in the 50- to 70-year age group. However, the data
clearly indicate that emergency operation and clot have
a negative impact on in-hospital and long-term outcome.
A carefully orchestrated aortic aneurysm surveillance pro-
gram and timely elective surgery can circumvent the higher
mortality and complication rates associated with emergency
operations.References
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